Next-Gen Clinical Trials: NLP, AI-MRI, Wearables, Psilocybin
Four converging pillars—NLP speech biomarkers, AI MRI, wearable biosensors, and digital psilocybin monitoring—are reshaping trial design, endpoints, and recruitment with measurable signal gains and faster go/no-go decisions.
Robert Maxwell
Oct 09, 2025
Primary Progressive Aphasia
Breast imaging biomarkers
Post-stroke wearables
psilocybin-assisted therapy